FibroGen CEO Enrique Conterno receives $12M in 2020
FibroGen reports 2020 executive compensation
By ExecPay News
Published: April 13, 2021
FibroGen reported fiscal year 2020 executive compensation information on April 13, 2021.
In 2020, eight FibroGen executives received on average a compensation package of $4.1M, a 32% decrease compared to previous year.
Average pay of disclosed executives at FibroGen
Enrique Conterno, Chief Executive Officer, received $12M in total. 65% of Conterno's compensation, or $8M, was in option awards. Conterno also received $250K in bonus, $554K in non-equity incentive plan, $791K in salary, $2.6M in stock awards, as well as $46K in other compensation.
For fiscal year 2020, the median employee pay was $177,952 at FibroGen. Therefore, the ratio of Enrique Conterno's pay to the median employee pay was 69 to one.
Thane Wettig, Chief Commercial Officer, received a compensation package of $4M. 54% of the compensation package, or $2.2M, was in option awards.
Mark Eisner, Chief Medical Officer, earned $3.9M in 2020.
K. Peony Yu, Chief Medical Officer, received $3.5M in 2020, which decreases by 40% compared to 2019.
Pat Cotroneo, Chief Financial Officer, earned $2.9M in 2020, a 33% decrease compared to previous year.
Elias Kouchakji, Senior Vice President, Clinical Development, Drug Safety, and Pharmacovigilance, received $2.9M in 2020, which decreases by 42% compared to 2019.
Christine L. Chung, Senior Vice President, China Operations, earned $2.9M in 2020, a 37% decrease compared to previous year.
James A. Schoeneck, Chief Executive Officer, received $717K in 2020, which decreases by 86% compared to 2019.
Related executives
Enrique Conterno
FibroGen
Chief Executive Officer
James Schoeneck
FibroGen
Chief Executive Officer
Pat Cotroneo
FibroGen
Chief Financial Officer
Mark Eisner
FibroGen
Chief Medical Officer
Elias Kouchakji
FibroGen
Senior Vice President, Clinical Development, Drug Safety, and Pharmacovigilance
Thane Wettig
FibroGen
Chief Commercial Officer
K Yu
FibroGen
Chief Medical Officer
Christine Chung
FibroGen
Senior Vice President, China Operations
You may also like
Source: SEC filing on April 13, 2021.